Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study Meeting Abstract
| Authors: | Van der Heijden, M. S.; Powles, T.; Gupta, S.; Bedke, J.; Kikuchi, E.; De Wit, R.; Galsky, M. D.; Duran, I.; Necchi, A.; Retz, M.; Yu, E. Y.; Hoffman-Censits, J. H.; Iyer, G.; Park, S. H.; Su, W. P.; Parmar, H.; Guan, X. S.; Gorla, S. R.; Moreno, B. H.; Valderrama, B. P. |
| Abstract Title: | Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study |
| Meeting Title: | 2024 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2024 Jan 25-27 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-02-01 |
| Language: | English |
| ACCESSION: | WOS:001266676900030 |
| DOI: | 10.1200/JCO.2024.42.4_suppl.LBA530 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA530 -- Source: Wos |
